Promising pancreatic cancer drug study halted before it began
NCT ID NCT07026916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a new drug called GFH375 in people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). The goal was to see if the drug could shrink tumors or slow the disease. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Smart drug delivers chemo directly to pancreatic cancer cells
- Gene-Guided chemo cocktail aims to tame tough pancreatic cancer
- New blood test could spot hidden cancer cells that spread
- Could a stomach drug help fight pancreatic cancer?
- Can a simple blood test replace scans for pancreatic cancer patients?